Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 11/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31405112 | 0.84 | PDCD1 (0.33) | OPRL1GRM2PDCD1CD274CNR2 | |
| SCHEMBL31405094 | 0.82 | RAF1 (0.34) | MAP4K4RAF1PDCD1CD274P2RX3 | |
| SCHEMBL31405032 | 0.82 | IL1B (0.41) | IL1BTNFGRM2NLRP3KCNH2 | |
| SCHEMBL31405060 | 0.82 | IL1B (0.51) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL31405098 | 0.80 | IL1B (0.48) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL31405089 | 0.77 | OPRL1 (0.39) | IL1BTNFOPRL1MAP4K4NLRP3 | |
| SCHEMBL31404970 | 0.76 | CNR2 (0.39) | IL1BOPRL1NLRP3CNR2 | |
| SCHEMBL31405022 | 0.76 | IL1B (0.54) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL31405104 | 0.76 | IL1B (0.41) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL31404988 | 0.76 | IL1B (0.41) | IL1BTNFNLRP3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | IL1B 1/4885TNF 53/4885OPRL1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.